[{"orgOrder":0,"company":"GenBio","sponsor":"Strainsforpains","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"GenBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenBio \/ Strainsforpains","highestDevelopmentStatusID":"5","companyTruncated":"GenBio \/ Strainsforpains"}]

Find Clinical Drug Pipeline Developments & Deals by GenBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Under the agreement, GenBio will license potentially new, next generation of anti-inflammatory cannabinoids to be included in Strainsforpains CBD branded products.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Strainsforpains

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank